Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Anitocabtagene autoleucel by Arcellx for Refractory Multiple Myeloma: Likelihood of Approval
Anitocabtagene autoleucel is under clinical development by Arcellx and currently in Phase III for Refractory Multiple Myeloma. According to GlobalData,...
Anitocabtagene autoleucel by Arcellx for Relapsed Multiple Myeloma: Likelihood of Approval
Anitocabtagene autoleucel is under clinical development by Arcellx and currently in Phase III for Relapsed Multiple Myeloma. According to GlobalData,...
ACLX-002 by Arcellx for Myelodysplastic Syndrome: Likelihood of Approval
ACLX-002 is under clinical development by Arcellx and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I...
ACLX-002 by Arcellx for Refractory Acute Myeloid Leukemia: Likelihood of Approval
ACLX-002 is under clinical development by Arcellx and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData,...
ACLX-002 by Arcellx for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
ACLX-002 is under clinical development by Arcellx and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData,...